Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Creative Medical Technology Holdings (CELZ) EBIT (2016 - 2025)

Creative Medical Technology Holdings (CELZ) has disclosed EBIT for 16 consecutive years, with -$1.9 million as the latest value for Q4 2025.

  • Quarterly EBIT fell 3.18% to -$1.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$6.1 million through Dec 2025, down 6.95% year-over-year, with the annual reading at -$6.1 million for FY2025, 6.95% down from the prior year.
  • EBIT for Q4 2025 was -$1.9 million at Creative Medical Technology Holdings, down from -$1.3 million in the prior quarter.
  • The five-year high for EBIT was -$303944.0 in Q1 2021, with the low at -$6.3 million in Q4 2022.
  • Average EBIT over 5 years is -$1.5 million, with a median of -$1.3 million recorded in 2025.
  • The sharpest move saw EBIT plummeted 355.86% in 2021, then skyrocketed 71.78% in 2023.
  • Over 5 years, EBIT stood at -$1.5 million in 2021, then tumbled by 326.28% to -$6.3 million in 2022, then surged by 71.78% to -$1.8 million in 2023, then dropped by 6.43% to -$1.9 million in 2024, then dropped by 3.18% to -$1.9 million in 2025.
  • According to Business Quant data, EBIT over the past three periods came in at -$1.9 million, -$1.3 million, and -$1.3 million for Q4 2025, Q3 2025, and Q2 2025 respectively.